176 related articles for article (PubMed ID: 21083028)
61. Histamine in cancer immunotherapy.
Hellstrand K; Hermodsson S; Brune M; Naredi P; Carneskog J; Mellqvist UH
Scand J Clin Lab Invest; 1997 May; 57(3):193-202. PubMed ID: 9238754
[TBL] [Abstract][Full Text] [Related]
62. Immunosuppression and Immunotargeted Therapy in Acute Myeloid Leukemia - The Potential Use of Checkpoint Inhibitors in Combination with Other Treatments.
Leufven E; Bruserud Ø
Curr Med Chem; 2019; 26(28):5244-5261. PubMed ID: 30907305
[TBL] [Abstract][Full Text] [Related]
63. [Advances in targeted therapy for childhood acute myeloid leukemia].
Wang NN; Ye QD
Zhongguo Dang Dai Er Ke Za Zhi; 2017 Jul; 19(7):832-836. PubMed ID: 28697841
[TBL] [Abstract][Full Text] [Related]
64. [Recent Advances in Immunotherapy for Acute Myeloid Leukemia --Review].
Xu B; Xiao Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Apr; 27(2):633-636. PubMed ID: 30998183
[TBL] [Abstract][Full Text] [Related]
65. Immunotherapy in the treatment of acute myelogenous leukemia (AML): rationale, results and future prospects.
Urbanitz D; Büchner T; Pielken H; van de Loo J
Klin Wochenschr; 1983 Oct; 61(19):947-54. PubMed ID: 6196515
[TBL] [Abstract][Full Text] [Related]
66. Leukocytoclastic vasculitis and long-term remission in a patient with secondary AML and post-remission treatment with low-dose interleukin-2.
Engelhardt M; Rump JA; Hellerich U; Mertelsmann R; Lindemann A
Ann Hematol; 1995 Apr; 70(4):227-30. PubMed ID: 7748968
[TBL] [Abstract][Full Text] [Related]
67. Immunotherapy for Acute Myeloid Leukemia: Current Trends, Challenges, and Strategies.
Chen EC; Garcia JS
Acta Haematol; 2024; 147(2):198-218. PubMed ID: 37673048
[TBL] [Abstract][Full Text] [Related]
68. Histamine: a novel approach to cancer immunotherapy.
Hellstrand K; Brune M; Naredi P; Mellqvist UH; Hansson M; Gehlsen KR; Hermodsson S
Cancer Invest; 2000; 18(4):347-55. PubMed ID: 10808371
[TBL] [Abstract][Full Text] [Related]
69. Molecular Changes During Acute Myeloid Leukemia (AML) Evolution and Identification of Novel Treatment Strategies Through Molecular Stratification.
Karjalainen E; Repasky GA
Prog Mol Biol Transl Sci; 2016; 144():383-436. PubMed ID: 27865463
[TBL] [Abstract][Full Text] [Related]
70. Old cancer drug gets fresh look.
Ledford H
Nature; 2014 May; 509(7502):541-2. PubMed ID: 24870520
[No Abstract] [Full Text] [Related]
71. Interleukin-2 may induce prolonged remissions in advanced acute myelogenous leukemia.
Meloni G; Foa R; Vignetti M; Guarini A; Fenu S; Tosti S; Tos AG; Mandelli F
Blood; 1994 Oct; 84(7):2158-63. PubMed ID: 7919330
[TBL] [Abstract][Full Text] [Related]
72. A targeted graphene nanoplatform carrying histamine dihydrochloride for effective inhibition of leukemia-induced immunosuppression.
Cherukula K; Nurunnabi M; Jeong YY; Lee YK; Park IK
J Biomater Sci Polym Ed; 2018; 29(7-9):734-749. PubMed ID: 28994338
[TBL] [Abstract][Full Text] [Related]
73. Pathogenic and therapeutic roles of cytokines in acute myeloid leukemia.
Karimdadi Sariani O; Eghbalpour S; Kazemi E; Rafiei Buzhani K; Zaker F
Cytokine; 2021 Jun; 142():155508. PubMed ID: 33810945
[TBL] [Abstract][Full Text] [Related]
74. Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia.
Vadakekolathu J; Minden MD; Hood T; Church SE; Reeder S; Altmann H; Sullivan AH; Viboch EJ; Patel T; Ibrahimova N; Warren SE; Arruda A; Liang Y; Smith TH; Foulds GA; Bailey MD; Gowen-MacDonald J; Muth J; Schmitz M; Cesano A; Pockley AG; Valk PJM; Löwenberg B; Bornhäuser M; Tasian SK; Rettig MP; Davidson-Moncada JK; DiPersio JF; Rutella S
Sci Transl Med; 2020 Jun; 12(546):. PubMed ID: 32493790
[TBL] [Abstract][Full Text] [Related]
75. The combination of chemotherapy and systemic immunotherapy and the concept of cure in murine leukemia and lymphoma.
Dunussi-Joannopoulos K
Leuk Lymphoma; 2002 Nov; 43(11):2075-82. PubMed ID: 12533031
[TBL] [Abstract][Full Text] [Related]
76. Polyethylene glycolated interleukin-2 as maintenance therapy for acute myelogenous leukemia in second remission.
Wiernik PH; Dutcher JP; Todd M; Caliendo G; Benson L
Am J Hematol; 1994 Sep; 47(1):41-4. PubMed ID: 8042615
[TBL] [Abstract][Full Text] [Related]
77. Acute myeloid leukemia cell membrane-coated nanoparticles for cancer vaccination immunotherapy.
Johnson DT; Zhou J; Kroll AV; Fang RH; Yan M; Xiao C; Chen X; Kline J; Zhang L; Zhang DE
Leukemia; 2022 Apr; 36(4):994-1005. PubMed ID: 34845316
[TBL] [Abstract][Full Text] [Related]
78. Two decades of targeted therapies in acute myeloid leukemia.
Cucchi DGJ; Polak TB; Ossenkoppele GJ; Uyl-De Groot CA; Cloos J; Zweegman S; Janssen JJWM
Leukemia; 2021 Mar; 35(3):651-660. PubMed ID: 33589753
[TBL] [Abstract][Full Text] [Related]
79. Alleviating oxidative stress in cancer immunotherapy: a role for histamine?
Hellstrand K; Brune M; Dahlgren C; Hansson M; Hermodsson S; Lindnér P; Mellqvist UH; Naredi P
Med Oncol; 2000 Nov; 17(4):258-69. PubMed ID: 11114704
[TBL] [Abstract][Full Text] [Related]
80. AML therapy in the elderly: a time for a change.
Isidori A; Loscocco F; Visani G
Expert Opin Drug Saf; 2016 Jul; 15(7):891-2. PubMed ID: 27054576
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
